Review Article

World Journal of Pediatrics

, Volume 9, Issue 3, pp 212-220

First online:

Treatment of children with chronic viral hepatitis: what is available and what is in store

  • Pietro VajroAffiliated withDepartment of Medicine and Surgery, University of SalernoDepartment of Medicine and Surgery, University of Salerno Email author 
  • , Claudio VeropalumboAffiliated withDepartment of Translational Medical Sciences, Pediatrics, University of Naples “Federico II”
  • , Sergio MaddalunoAffiliated withDepartment of Translational Medical Sciences, Pediatrics, University of Naples “Federico II”
  • , Mariacarolina SalernoAffiliated withDepartment of Translational Medical Sciences, Pediatrics, University of Naples “Federico II”
  • , Giancarlo ParentiAffiliated withDepartment of Translational Medical Sciences, Pediatrics, University of Naples “Federico II”
  • , Claudio PignataAffiliated withDepartment of Translational Medical Sciences, Pediatrics, University of Naples “Federico II”

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

At present, therapy of children with chronic hepatitis B and C is still based on few drugs, all burdened by a series of side-effects, unsatisfactory serum conversion rates, and/or drug-resistance. Moreover, selection of subjects to treat with conventional therapies is not univocal, especially during the pediatric age when the disease course is often mild with significant spontaneous seroconversion rate. Our review deals with pros and cons points when a physician decides to design a drug therapy for a child with chronic viral hepatitis, and different possible therapeutic opportunities.

Methods

A literature search was performed through PubMed. The newest articles, reviews, systematic reviews, and guidelines were included in this review.

Results

The management of children with viral hepatitis is still controversial over whom and when to treat and the use of drug(s). Novel therapeutic strategies have been evaluated only in clinical and preclinical trials involving, for instance, “therapeutic” vaccines. The data on safety and effectiveness of new drugs are also reviewed.

Conclusion

The results of reported studies confirmed that at least some of the new drugs, with greater efficacy and/or minor side-effects, will be used clinically.

Key words

children hepatitis B hepatitis C therapy